If ultimately approved, the drug, aducanumab, made by Biogen, would be the first new Alzheimer’s treatment in nearly two decades. Some evidence suggests it slows, but does not stop, cognitive decline.. via NYT Health https://ift.tt/3jZ7hgp

Products You May Like

Leave a Reply

Your email address will not be published. Required fields are marked *